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Background
Fucoidan is a highly sulfated glycosaminoglycan, which has a molecular structure similar 
to that of heparin. The antithrombotic effects of fucoidan in vitro have been widely re-
ported, but its antithrombotic effects in vivo as well as its other biological properties in 
vitro have not been well investigated.
Methods
This study investigated the effects and mechanism of fucoidan from Fucus vesiculosus 
on thrombosis both in vitro and in vivo. A ferric chloride-induced mouse carotid artery 
thrombosis model was used to determine the antithrombotic effects of fucoidan in vivo. 
Additionally, changes in the levels of proinflammatory cytokines and chemokines were 
examined in vascular cells treated with fucoidan.
Results
In vivo studies employing a ferric chloride-induced mouse carotid artery thrombosis mod-
el indicated that fucoidan had a stronger antithrombotic activity than heparin. Further, 
vascular cells treated with fucoidan demonstrated a decrease in proinflammatory cyto-
kine and chemokine production as well as inhibition of proliferation.
Conclusion
The major findings of this study showed that fucoidan has a stronger antithrombotic effect 
than heparin in vivo and that fucoidan has an inhibitory effect on proinflammatory cytokine 
production and proliferation of vascular cells.
Key Words Fucoidan, Fucus vesiculosus, Antithrombotic effect, Proinflammatory 
cytokines, Vascular cell proliferation
Correspondence to
Kwang-Hoe Chung, Ph.D.
Thrombosis and Vascular Biology Lab., 
Department of Medical Science, CHA 





Ⓒ2010 The Korean Journal of Hematology
INTRODUCTION
  Fucoidan is a highly sulfated glycosaminoglycan, which 
has a molecular structure similar to that of heparin, and 
its antithrombotic effects in vitro have been widely reported 
[1-3]. Although fucoidan and heparin have similar structures, 
fucoidan exerts strong antiproliferative effects on smooth 
muscle cells (SMCs) [4] and also on heparin-resistant SMCs 
[5]. Furthermore, fucoidan can modulate the proliferation 
of fibroblasts [6].
  The pathogenesis of atherothrombotic diseases such as 
stroke, myocardial infarction, and restenosis after angioplasty 
affects vascular SMC proliferation, human umbilical vascular 
endothelial cell (HUVEC) inflammation, and platelet ag-
gregation [7, 8]. In addition, the major component of reste-
nosis after stent implantation is intimal hyperplasia due to 
migration and proliferation of vascular SMCs from the media 
to the intima [9, 10].
  In this study, we tried to investigate the effects and in-
hibitory mechanism of fucoidan on thrombosis, both in vitro 
and in vivo, as well as on vascular cells. Therefore, we first 
evaluated the antithrombotic effects of fucoidan on blood 
coagulation factors and platelet aggregation in vitro. We 
also examined the antithrombotic effect and mechanism of 
fucoidan in a mouse carotid artery thrombosis model because 
not many reports are available on the antithrombotic effects 
of fucoidan in vivo ( i . e . ,  i n  a n  a r t e r y  i n j u r y  m o d e l ) .  
Furthermore, we investigated the effects of fucoidan on SMCs Korean J Hematol 2010;45:51-7.
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and HUVECs, which play a key role in atherosclerotic vas-
cular diseases. In particular, the change in the inflammatory 
factors in vascular cells was analyzed by Multiplex cytokine 
assay system.
MATERIALS AND METHODS
1. Ferric chloride (FeCl3)-induced mouse thrombosis model
  Slc:ICR mice (6-8 weeks old males; weight, 30-33 g) were 
purchased from Jungang Animal Co., Seoul, Korea. Thrombo-
sis was induced in mice using a previously described carotid 
artery injury model [11]. Three mice were used for each 
concentration. After an intraperitoneal injection containing 
both 2.5 mL/kg Zoletil (Virbac Animal Health Co., Carros, 
France) and 0.3 mL/kg Rompun (Bayer Korea, Anseong, 
Korea) for anesthesia, the skin on the upper central neck 
area was directly incised and the left common carotid artery 
was exposed. Carotid artery blood flow was measured with 
a miniature Doppler flow probe (diameter: 2 mm) for photo-
plethysmography (BioBud Inc., Seoul, Korea). Total occlu-
sion was induced by applying a strip of filter paper (1×1 
mm) saturated with 25% FeCl3 proximal to the surface of 
the carotid artery for 3 min. The carotid blood flow was 
monitored from time 0 (before the application of the FeCl3 
paper) up to the time of occlusion. Various concentrations 
(0, 0.05, 0.07, and 0.1 mg/kg body weight) of fucoidan (Sigma 
Chemical Co., St. Louis, MO, USA) or high-molecular- 
weight heparin (100 KU, Grade I-A, Sigma Chemical Co) 
were intravenously injected just before blood flow monito-
ring. The concentrations of heparin were 0, 0.05, 0.07, 0.1, 
0.13, 0.16, and 0.2 mg/kg body weight.
2. Platelet aggregation assay
  The platelet aggregation assay was performed in human 
platelet-rich plasma (PRP). The platelet concentrate was di-
luted to 300,000 cells/μL of platelet-poor plasma (PPP). Ten 
microliters of samples (fucoidan, heparin, and phos-
phate-buffered saline [PBS]) was added to 450 μL of plasma 
and incubated for 2 min in an incubation well of the platelet 
aggregometer (Chrono-Log Co., Havertown, PA, USA) at 
37
oC. The final concentrations of fucoidan and heparin in 
this experiment were 0, 0.2, 0.4, 0.6, 0.8, and 1 μg/mL. 
The impedance was recorded, and ADP (20 μM) was added 
in order to initiate platelet aggregation. The inhibition of 
platelet aggregation was measured at the maximum ag-
gregation response and the IC50 value was calculated by 
the least squares method.
3. Inhibition of thrombin and factor Xa by antithrombin in the 
presence of fucoidan or heparin
   The anti-thrombin and anti-factor Xa activities of fucoi-
dan were determined by chromogenic assay methods. In 
a 1.5 mL tube that contained thrombin (0.1 units/mL) or 
factor Xa (0.005 units/mL) in a buffer (pH 8.8) containing 
50 mM Tris-HCl and 38 mM NaCl and antithrombin (0.1 
μg/mL), various concentrations (0, 1, 5, 10, 50, 100, and 
500 μg/mL) of fucoidan or heparin (180 IU/mg) were added, 
and the tubes were incubated at 37
oC for 20 min. After 
incubation, 25 μL of the solution from each 1.5 mL tube 
was transferred to a well of a 96-well plate. Then, 200 μL 
of 50 mM Tris-HCl (pH 8.8) buffer and 25 μL of thrombin 
substrate (0.3 mM/mL) or factor Xa substrate (0.3 mM/mL) 
were added to each well of the 96-well plate and incubated 
for 60 min at 37
oC. After incubation, amidolytic activities 
were measured using a spectrophotometer at 405 nm.
4. Coagulation parameters 
  PPP was obtained by centrifugation of citrated human 
blood at 1,200×g for 15 min. The plasma was incubated 
with fucoidan dissolved in PBS (plasma：PBS=1：4), heparin 
dissolved in PBS, or only PBS for 2 min at 37
oC. The plasma 
clotting times, activated partial thromboplastin time (aPTT) 
(Hyphen-BioMed, Andresy, France), prothrombin time (PT) 
(Hyphen-BioMed), and thrombin time (TT) (Hyphen- 
BioMed) were measured using the blood coagulometer 
Thrombotimer 2 (Behnk Elektronik, Norderstedt, Germany).
5. Rat aortic smooth muscle cell (RAoSMC) culture and pro-
liferation assay
  RAoSMCs were obtained from BioBud Inc. (Seoul, Korea). 
The cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco Life Technologies, Gaithersburg, 
MD, USA) containing 10% fetal bovine serum (Welgene 
Co., Daegu, Korea), 3.7% sodium bicarbonate, and 1% pen-
icillin-streptomycin (10,000 IU/mL; Gibco Life Technolog-
ies). RAoSMCs were used between the fourth and eighth 
passages. The cells were incubated in 96-well plates (Corning 
Costar, Cambridge, MA, USA) at a density of 5×10
4 cells/well. 
After 24 h, the medium was changed with 100 μL fresh 
media containing several different concentrations (0, 50, 100, 
500, and 1,000 μg/mL) of fucoidan and high-molec-
ular-weight heparin. After changing the media, cells were 
further incubated for 24, 48, and 72 h at 37
oC. Assays for 
cell proliferation were performed using a CCK-8 kit (Dojindo 
Molecular Technologies Inc, MA, USA). The samples were 
read at 450 nm using a spectrophotometer VERSAmax
TM 
Tunable Microplate Reader (Molecular Devices Corp., CA, 
USA).
6. SMC migration assay 
  The effect of fucoidan on SMC migration was examined 
by performing a modified Boyden chamber assay in Transwell 
cell culture chambers using a polycarbonate membrane with 
8 μm pores in a 6-well plate. RAoSMCs were suspended 
in serum-free DMEM at a concentration of 5×10
5 cells/mL. 
Cells were then pretreated with several concentrations of 
fucoidan and heparin for 30 min at 37
oC. Serum-free DMEM 
was added to the lower compartment. Cell suspensions were 
added to the upper compartment and were then incubated 
for 6 h at 37
oC. The cells were fixed and stained with crystal 
violet. The filter membranes were dried and the migrated 
cells were counted.Korean J Hematol 2010;45:51-7.
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Fig. 1. Ferric chloride-induced mouse carotid artery thrombosis model. (A) Expose of left common carotid artery, (B) Induction of total occlusion 
by applying a filter paper saturated with 25% ferric chloride solution, (C) Monitoring of carotid blood flow with micro-optical probe, (D)
Photoplethysmography of carotid blood flow until time to occlusion.
7. SMC adhesion assay
  Ninety-six-well plates were precoated with vitronectin, 
fibronectin, and laminin (500 μg/mL) at 4
oC overnight. SMCs 
(3×10
5 cells/well) were preincubated with fucoidan and hep-
arin for 30 min at 37
oC. After incubation, the cells were 
transferred to each well and incubated for 1 h at 37
oC in 
5% CO2. Unattached cells were removed by washing with 
PBS. Attached cells were fixed and stained with crystal violet. 
The plates were read using a spectrophotometer at 490 nm 
to determine the relative number of cells.
8. Mutiplex cytokine assays in HUVECs 
  HUVECs were plated onto 96-well cell culture plates coat-
ed with 0.5% gelatin. After 24 h, the serum-free media con-
taining fucoidan and heparin were changed and the plate 
was incubated for 8 h at 37
oC in a CO2 atmosphere; the 
cells were then stimulated with tumor necrosis factor-alpha 
(TNFα) (10 ng/mL) for 16 h in an incubator. After in-
cubation, supernatants were collected for the determination 
of the inflammatory cytokine levels using a Multiplex cyto-
kine assay system (Luminex 100
TM IS Total System, XMAP 
technology, Millipore, MA, USA). Sixteen kinds of in-
flammatory cytokines and/or chemokines (Eotaxin, gran-
ulocyte-macrophage colony-stimulating factor [GM-CSF], 
interferon (IFN)-α2, IFNγ, interleukin (IL)-10, IL-12, IL-1
α, IL-1β, IL-1Rα, IL-2, IL-6, IP-10, monocyte chemo-
attractant protein (MCP)-1, RANTES, TNF-α, and TNF-β) 
were quantitatively determined.
RESULTS 
1. Inhibitory effect of fucoidan in a mouse carotid artery 
thrombosis model
  A FeCl3-induced mouse carotid artery occlusion model 
was developed and well optimized to evaluate the antith-
rombotic activity of anticoagulants and thrombolytic agents 
(Fig. 1). Before drug treatment, the average total occlusion 
time was determined as 12.5 min. Antithrombotic activity 
(effective dose, 50% [ED50]) was calculated as the concen-
tration required to double the total occlusion time. The ED50 
values of fucoidan and heparin were approximately 0.54 
and 1.24 mg/kg body weight, respectively. Therefore, fucoi-
dan showed approximately 2.3 times stronger antithrombotic 
effect than heparin in vivo (Fig. 2).Korean J Hematol 2010;45:51-7.
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Fig. 2. The inhibitory effect of fucoidan in an in vivo mouse thrombosis 
model. The antithrombotic effect of fucoidan was 2.3 times stronger 
than heparin in a ferric chloride-induced mouse carotid artery occlu-
sion model. The time to delay occlusion twice was represented as the
ED50 value.
Fig. 3.  The inhibitory effect of fucoidan on platelet aggregation (n=3).
The inhibitory effect of fucoidan on platelet aggregation was approxi-
mately 2.8 times stronger than that of heparin (Error bar is not shown).
Fig. 4. The inhibitory effect of fucoidan and heparin on thrombin (A) and factor Xa (B) by antithrombin. The enzyme activities were determined by 
chromogenic assay methods.
2. Inhibitory effect of fucoidan on platelet aggregation
  Fucoidan strongly inhibited ADP-induced human platelet 
aggregation in vitro in a concentration-dependent manner. 
The 50% inhibitory concentrations (IC50 values) of fucoidan 
and heparin for platelet aggregation were determined as 
0.36 and 1.0 μg/mL, respectively (Fig. 3). Therefore, the 
inhibitory effect of fucoidan on platelet aggregation is ap-
proximately 2.8 times superior to that of heparin.
3. Anti-thrombin and anti-factor Xa activities of fucoidan
  The anti-thrombin and anti-factor Xa activities of fucoidan 
were interestingly weaker than those of heparin (Fig. 4), 
although the overall antithrombotic effect of fucoidan in 
vivo was even more potent than that of heparin (data not 
shown).
4. Effects of fucoidan on PT, aPTT, and TT
  The anticoagulation activities of fucoidan, as determined 
by aPTT (Table 1), PT (data not shown), and TT (data not 
shown), were revealed to be dose dependent, although hep-Korean J Hematol 2010;45:51-7.
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Fig. 5. The inhibitory effect of fucoidan on SMC proliferation. The 
antiproliferative effect of fucoidan on SMC was stronger than that of 
heparin. Cell proliferation was inhibited at 50 μg/mL of both fucoidan 
and heparin. Above a concentration of 500 μg/mL, fucoidan showed a 
stronger antiproliferative effect on SMCs than heparin. *P＜0.01
Fig. 6. Change in the levels of inflammatory cytokines in HUVECs after treatment with fucoidan. HUVECs were pre-incubated with fucoidan for 8 
h and then further incubated for 16 h in the presence of 10 ng/mL TNF-alpha.
arin showed considerably higher inhibitory activity on PT, 
aPTT, and TT than fucoidan.
5. Inhibitory effects of fucoidan on SMC proliferation, migra-
tion, and adhesion
  We tested the inhibitory effects of fucoidan on RAoSMC 
proliferation, migration, and adhesion. In proliferation as-
says, we found that fucoidan had a stronger inhibitory effect 
on SMC proliferation than heparin (Fig. 5). In addition, fucoi-
dan inhibited SMC migration and SMC adhesion to ex-
tracellular matrix to a greater extent than heparin (data not 
shown). Specially, fucoidan inhibited SMC adhesion to lam-
inin in a dose-dependent manner.
6. Effects of fucoidan on cytokine production in HUVECs
    Sixteen kinds of cytokines were simultaneously de-
termined by the Multiplex assay system. We confirmed that 
the levels of some specific inflammatory cytokines and che-
mokines were reduced in HUVECs when we treated the 
cells with fucoidan in the presence of TNF-α. Specifically, 
fucoidan treatment reduced the amounts of GM-CSF, IL-6, 
MCP-1, and RANTES (Fig. 6). In addition, fucoidan showed Korean J Hematol 2010;45:51-7.
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a stronger inhibitory effect on the proinflammatory cytokines 
than heparin.
DISCUSSION
  The purpose of this study was to investigate the effects 
and mechanism of fucoidan on thrombosis both in vitro 
and in vivo and in vascular cells such as SMCs and endothelial 
cells. Because many reports are not available on the antith-
rombotic effect of fucoidan in vivo, we optimized a FeCl3- 
induced mouse carotid artery occlusion model by the mod-
ification of a previous model [11] to evaluate the antith-
rombotic effects of fucoidan. 
  The antithrombotic activities of fucoidan in vitro were 
similar to those reported by other groups [12-17]. However, 
in in vivo studies using a mouse thrombosis model, fucoidan 
showed stronger antithrombotic activities than heparin. To 
define the antithrombotic mechanism of fucoidan, we exam-
ined the effects of fucoidan on blood coagulation factors 
and platelet aggregation in vitro. The anti-thrombin and 
anti-factor Xa activities of fucoidan in vitro were weaker 
than those of heparin (Fig. 4), suggesting that the stronger 
antithrombotic activities of fucoidan in vivo might be caused 
by its binding with heparin cofactor II rather than with 
antithrombin. The potent anti-thrombin and anti-factor Xa 
activities of heparin in vitro may be due to the increase 
in its binding affinity with antithrombin.
  The effects of fucoidan and heparin on coagulation time 
have also been examined by aPTT, PT, and TT assays in 
human PPP. The anticoagulant activity of heparin was much 
stronger than fucoidan in this experiment. Therefore, it could 
be concluded that the antithrombotic mechanism of fucoidan 
is different from that of heparin. 
  One of the major causes of restenosis after stenting is 
SMC proliferation and migration [9, 10]. A previous report 
demonstrated that the mechanism of the antimitogenic effect 
of fucoidan was different from that of heparin, which also 
inhibits SMC growth [18]. As expected, fucoidan inhibited 
proliferation and migration of SMCs to a greater extent than 
heparin [19]. 
  It has recently been accepted that atherosclerosis and reste-
nosis are an inflammatory process [20, 21]. To examine the 
effects of fucoidan and heparin on the production of cyto-
kines in HUVECs, we determined the change in the in-
flammatory cytokines in HUVECs treated with fucoidan by 
the Multiplex assay system. Interestingly, the levels of several 
proinflammatory cytokines such as GM-CSF, IL-6, MCP-1, 
and RANTES were dramatically reduced in HUVECs treated 
with fucoidan. 
  In conclusion, fucoidan showed a stronger antithrombotic 
effect than heparin in vivo, antiproliferative effect on SMCs, 
and anti-inflammatory effect on HUVECs. Considering these 
results together, we can suggest that fucoidan may be useful 
for the prevention of cardiovascular diseases.
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